What is DNA Script?
Founded in 2014, DNA Script is a pioneering biotechnology firm that has developed a faster, more versatile alternative to traditional chemical DNA synthesis. Its core innovation, Enzymatic DNA Synthesis (EDS), allows for the rapid, on-demand production of nucleic acids directly within the laboratory environment. By launching the SYNTAX System, the company has effectively bridged the gap between complex genomic research and accessible, benchtop manufacturing. This technological shift is critical for labs focused on synthetic biology, drug discovery, and molecular diagnostics, as it removes the bottlenecks associated with outsourced synthesis services and long lead times.
How much funding has DNA Script raised?
DNA Script has raised a total of $302M across 3 funding rounds:
Series A
$13M
Series B
$89M
Series C
$200M
Series A (2017): $13M with participation from Illumina Ventures
Series B (2020): $89M led by Bpifrance Large Venture Fund, Life Sciences Partners, Agilent Technologies, Danaher Life Sciences, Illumina Ventures, M Ventures, and Casdin Capital
Series C (2021): $200M supported by Coatue and Catalio Capital Management
Key Investors in DNA Script
Illumina Ventures
Illumina Ventures is a leader in genomics and precision health investing, focused on building an ecosystem that translates investment into innovation to enhance human health.
Agilent Technologies
Agilent Technologies is a global leader in life sciences, diagnostics, and applied markets, providing laboratories worldwide with advanced instruments, software, and services.
M Ventures
M Ventures is the strategic, corporate venture capital arm of Merck, investing globally in transformational ideas and early-stage technologies to drive commercial success.
What's next for DNA Script?
With the recent influx of capital, DNA Script is well-positioned to accelerate the commercial adoption of its EDS platform on a global scale. The strategic focus will likely shift toward expanding the capabilities of the SYNTAX System, enhancing throughput, and broadening the range of applications for its enzymatic technology. As the company scales, it will continue to leverage its strong network of institutional partners to penetrate deeper into the biopharmaceutical and clinical research markets. The objective remains clear: to establish EDS as the industry standard for DNA synthesis, thereby catalyzing a new era of innovation in genomics and precision medicine.
See full DNA Script company page
